• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Immunogenicity of the hepatitis B vaccine adjuvanted with AS04C in patients with biological therapies
【24h】

Immunogenicity of the hepatitis B vaccine adjuvanted with AS04C in patients with biological therapies

机译：Immunogenicity of the hepatitis B vaccine adjuvanted with AS04C in patients with biological therapies

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

Background: Hepatitis B vaccination is necessary for patients with biologic therapies because of the immunomodulatory effect of these drugs. Due to the elevated use of these therapies in the latest years, the research for new vaccination regimens and the improvement of the current ones is essential. New adjuvants like AS04C might be a potential strategy to improve immune response. Hepatitis B vaccine adjuvanted with AS04C has not been studied in this population before. We analyzed the Immunogenicity of an adjuvanted hepatitis B vaccine in patients with biologic ther-apies. Variables that might affect vaccine response were also evaluated. Methods: Analytic observational retrospective cohort study performed between January 2016 and September 2018. 301 patients under biological treatment aged from 18 years were included. Patients received 4 doses of hepatitis B adjuvanted vaccine (Fendrix (R)) in a 0-1-2-6 month immunization sched-ule. Several sociodemographic, clinical and pharmacological variables were evaluated. The outcome vari-able was measured as the antibody titers (anti-HBs). The geometric mean of titers (GMT) as a measure for the central tendency was calculated from these values. Results: The immunization schedule of the hepatitis B vaccine adjuvanted with AS04C demonstrated high levels of seroconversion with 82.1 % (95 % CI, 77.6-86.6) of vaccinated patients seroconverting after pri-mary vaccination and achieving 89.0 % (95 % IC, 85.3-92.7) after the booster doses for non-responders. The use of corticosteroid therapy and high doses of them, age over 60 years and the main diagnosis were associated with lower seroconversion rates and lower anti-HBs titers.Conclusions: The hepatitis B vaccine adjuvanted with AS04C (Fendrix (R)) produces an adequate immune response in patients with autoimmune diseases and immunosuppressive and/or immunomodulating therapies. This immunization schedule is proposed as a very suitable and adapted option for the protec-tion of patients with autoimmune diseases under active biological therapies.(c) 2022 Elsevier Ltd. All rights reserved.

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号